PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12016742::ACT015695

GI

Evidence text

Paper-level observation

this multivalent nanoconjugate induced potent antigen‐specific anti‐tumor immune responses compared to StCl‐GI (P = 0.0218), as shown by the frequency of splenic positive cells for tetramers that bind to T cell receptor‐specific for the gp100 peptide epitope (Figure 4h).
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
P = 0.0218 vs StCl-GI
Normalized measurement
=0.0218
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Mus musculus
Assay method
Not reported by source
Sequence
EGSRNQDWL
Standardization
ready simple

Source publication

Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

Advanced Materials · 2025

DOI 10.1002/adma.202417348 PMC12016742
Parent mention

Related peptide identities

PEPDIA-PLP-000563

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.